Momenta Pharmaceuticals said Monday that it is cutting its workforce by half — a reduction of 110 jobs — and will gut much of its leadership team as part of a dramatic restructuring at the Cambridge, Mass., biotech.

The drug maker is also reducing the amount of money it spends developing generic versions of costly biotechnology drugs, known as biosimilars, and will instead focus its resources on a pipeline of novel drug candidates for diseases stemming from problems with the immune system.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy